Humphreys BD - Search Results

1

Rapid development of hypertension and proteinuria with cediranib, an oral vascular endothelial growth factor receptor inhibitor.

Robinson ES, Matulonis UA, Ivy P, Berlin ST, Tyburski K, Penson RT, Humphreys BD. Robinson ES, et al. Among authors: humphreys bd. Clin J Am Soc Nephrol. 2010 Mar;5(3):477-83. doi: 10.2215/CJN.08111109. Epub 2010 Jan 7. Clin J Am Soc Nephrol. 2010. PMID: 20056761 Free PMC article. Clinical Trial.

2

Hypertension induced by vascular endothelial growth factor signaling pathway inhibition: mechanisms and potential use as a biomarker.

Robinson ES, Khankin EV, Karumanchi SA, Humphreys BD. Robinson ES, et al. Among authors: humphreys bd. Semin Nephrol. 2010 Nov;30(6):591-601. doi: 10.1016/j.semnephrol.2010.09.007. Semin Nephrol. 2010. PMID: 21146124 Free PMC article. Review.

3

Suppression of the nitric oxide pathway in metastatic renal cell carcinoma patients receiving vascular endothelial growth factor-signaling inhibitors.

Robinson ES, Khankin EV, Choueiri TK, Dhawan MS, Rogers MJ, Karumanchi SA, Humphreys BD. Robinson ES, et al. Among authors: humphreys bd. Hypertension. 2010 Dec;56(6):1131-6. doi: 10.1161/HYPERTENSIONAHA.110.160481. Epub 2010 Oct 18. Hypertension. 2010. PMID: 20956731 Free PMC article.

4

Management of antiangiogenic therapy-induced hypertension.

de Jesus-Gonzalez N, Robinson E, Moslehi J, Humphreys BD. de Jesus-Gonzalez N, et al. Among authors: humphreys bd. Hypertension. 2012 Sep;60(3):607-15. doi: 10.1161/HYPERTENSIONAHA.112.196774. Epub 2012 Jul 30. Hypertension. 2012. PMID: 22851729 Free PMC article. No abstract available.

5

Regorafenib induces rapid and reversible changes in plasma nitric oxide and endothelin-1.

de Jesus-Gonzalez N, Robinson E, Penchev R, von Mehren M, Heinrich MC, Tap W, Wang Q, Demetri G, George S, Humphreys BD. de Jesus-Gonzalez N, et al. Among authors: humphreys bd. Am J Hypertens. 2012 Oct;25(10):1118-23. doi: 10.1038/ajh.2012.97. Epub 2012 Jul 12. Am J Hypertens. 2012. PMID: 22785409 Free PMC article.

6

Adverse renal and metabolic effects associated with oral sodium phosphate bowel preparation.

Heher EC, Thier SO, Rennke H, Humphreys BD. Heher EC, et al. Among authors: humphreys bd. Clin J Am Soc Nephrol. 2008 Sep;3(5):1494-503. doi: 10.2215/CJN.02040408. Epub 2008 Jul 2. Clin J Am Soc Nephrol. 2008. PMID: 18596115 Free PMC article. Review.

7

Onco-nephrology: AKI in the cancer patient.

Lam AQ, Humphreys BD. Lam AQ, et al. Among authors: humphreys bd. Clin J Am Soc Nephrol. 2012 Oct;7(10):1692-700. doi: 10.2215/CJN.03140312. Epub 2012 Aug 9. Clin J Am Soc Nephrol. 2012. PMID: 22879433 Free PMC article. Review.

8

Renal failure associated with cancer and its treatment: an update.

Humphreys BD, Soiffer RJ, Magee CC. Humphreys BD, et al. J Am Soc Nephrol. 2005 Jan;16(1):151-61. doi: 10.1681/ASN.2004100843. Epub 2004 Dec 1. J Am Soc Nephrol. 2005. PMID: 15574506 Review. No abstract available.

9

Development and Validation of a Risk Prediction Model for Acute Kidney Injury After the First Course of Cisplatin.

Motwani SS, McMahon GM, Humphreys BD, Partridge AH, Waikar SS, Curhan GC. Motwani SS, et al. Among authors: humphreys bd. J Clin Oncol. 2018 Mar 1;36(7):682-688. doi: 10.1200/JCO.2017.75.7161. Epub 2018 Jan 10. J Clin Oncol. 2018. PMID: 29320311 Free PMC article.

10

Circulating Plasma Biomarkers in Biopsy-Confirmed Kidney Disease.

Schmidt IM, Sarvode Mothi S, Wilson PC, Palsson R, Srivastava A, Onul IF, Kibbelaar ZA, Zhuo M, Amodu A, Stillman IE, Rennke HG, Humphreys BD, Waikar SS. Schmidt IM, et al. Among authors: humphreys bd. Clin J Am Soc Nephrol. 2022 Jan;17(1):27-37. doi: 10.2215/CJN.09380721. Epub 2021 Nov 10. Clin J Am Soc Nephrol. 2022. PMID: 34759008 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

222 results

Search Page